CommercialCoverageMedium impact
Hematopoietic Cell Transplantation for Myelofibrosis (CPB 0838, reviewed 2025-12-09)
Aetna·Hematology, Oncology, Transplant Surgery·Medical Policy
We identified it
Aug 17, 2026
Summary
Aetna's updated policy (CPB 0838) clarifies medical necessity criteria for allogeneic hematopoietic cell transplantation (HCT) in myelofibrosis patients and explicitly classifies seven interventions as experimental/investigational, including autologous HCT, pre-HCT ruxolitinib, mutational profiling for prognosis, and AI-based risk stratification. Billing teams must ensure claims for covered allogeneic procedures meet the five specified medical necessity criteria, and reject or route to medical review any claims involving the seven listed experimental interventions.
Action Required
IMMEDIATE: Billing team must implement the following in claim processing system and encounter workflows:
1. COVERED PROCEDURES (CPT 38204-38205, 38207-38215, 38230, 38240, 38242 for allogeneic HCT only):
- Add requirement to claim submission: Verify ONE of five medical necessity criteria is documented: (a) RBC transfusion dependence, (b) platelet transfusion dependence OR frequent infarctions, (c) ANC <1000/mm³, (d) resistance to conservative therapy, or (e) intermediate/high-risk MF.
- Update EMR/billing encounter forms to include checkboxes for these five criteria.
- Providers must document which criterion applies BEFORE claim submission.
- Claims missing documented criterion will be DENIED.
2. EXPERIMENTAL/NON-COVERED INTERVENTIONS (DO NOT BILL):
- Deny or refer to medical review ALL claims for: (1) Mutational profiling/genetic biomarkers for HCT prognosis, (2) Pre-HCT ruxolitinib, (3) Splenic irradiation before HCT, (4) Autologous HCT (CPT 38232, 38241), (5) Allogeneic SCT + mesenchymal stem cell transfusion, (6) AI/machine learning for risk stratification, (7) Splenic irradiation before allogeneic transplant conditioning.
- Flag any claim with diagnosis D75.81 (myelofibrosis) using these codes/services for PRIOR REVIEW before payment.
3. WHO: Billing team and provider credentialing/EMR staff. Providers must be notified of documentation requirements via email and training.
4. CONSEQUENCES: Claims for covered procedures without proper medical necessity documentation will be denied. Claims for experimental interventions will not be reimbursed.